Results 141 to 150 of about 9,558 (217)

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy. [PDF]

HIV Med
Faggiano T, Yin J, Patel N, Karim A, Abulhosn K, Bamford L, Hill L.   +6 more
europepmc   +1 more source

Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort. [PDF]

J Antimicrob Chemother
Gagliardini R, De Benedittis S, Tavelli A, Lapadula G, Mazzotta V, Bruzzesi E, Cervo A, Carrozzo G, Saracino A, Rusconi S, Marchetti G, Ceccherini-Silberstein F, Antinori A, d'Arminio Monforte A, Muccini C, Icona Foundation Study Group .   +15 more
europepmc   +1 more source